#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA4705673	F	Agonist activity at human GPR52 expressed in HEK293 cells assessed as increase in cAMP levels incubated for 15 mins by Glosensor cAMP assay relative to N-(2-hydroxyethyl)-1-(4-(3-(trifluoromethyl)benzyl)pyridin-2-yl)indoline-4-carboxamide	Homo sapiens	37		cell-based format	Scientific Literature
2.	ALA4705674	F	Agonist activity at human GPR52 expressed in HEK293 cells assessed as increase in cAMP levels incubated for 15 mins by Glosensor cAMP assay	Homo sapiens	37		cell-based format	Scientific Literature
3.	ALA4806971	F	Agonist activity at GPR52 (unknown origin) expressed in CHO-K1 or HEK293 cells assessed as intracellular cAMP accumulation incubated for 1 hr by HTRF assay	Homo sapiens	208		cell-based format	Patent Bioactivity Data
4.	ALA4806972	F	In vivo agonist activity at GPR52 in po dosed C57BL/6 mouse assessed as inhibition of basal locomotor activity measured for 60 mins starting at 15 mins post-drug challenge	Mus musculus	1		organism-based format	Patent Bioactivity Data
5.	ALA4806973	F	In vivo agonist activity at GPR52 in C57BL/6 mouse assessed as inhibition of basal locomotor activity at 10 mg/kg, po measured for 60 mins starting at 15 mins post-drug challenge	Mus musculus	13		organism-based format	Patent Bioactivity Data
6.	ALA4806974	F	Antipsychotic activity in Sprague-Dawley rat assessed as inhibition of amphetamine-stimulated locomotor activity at 0.5 to 20 mg/kg, po administered 15 mins prior to amphetamine stimulation and measured for 30 to 60 mins post-drug dosage	Rattus norvegicus	1		organism-based format	Patent Bioactivity Data
7.	ALA4806975	T	Toxicity in Sprague-Dawley rat assessed as inhibition of basal locomotor activity at 20 mg/kg, po	Rattus norvegicus	1		organism-based format	Patent Bioactivity Data
8.	ALA4806976	F	Antipsychotic activity in Sprague-Dawley rat assessed as inhibition of amphetamine-induced disruption of prepulse inhibition at 5 to 20 mg/kg, po administered 15 mins prior to amphetamine challenge and measured after 15 mins	Rattus norvegicus	1		organism-based format	Patent Bioactivity Data
9.	ALA4806977	F	Antipsychotic activity in Sprague-Dawley rat assessed as inhibition of MK801-induced disruption of prepulse inhibition at 5 to 20 mg/kg, po administered 15 mins prior to amphetamine challenge and measured after 15 mins	Rattus norvegicus	1		organism-based format	Patent Bioactivity Data
10.	ALA4806978	F	Increase in PPI in 129Sv/Ev mouse with low PPI at 10 mg/kg, po measured after 30 mins	Mus musculus	1		organism-based format	Patent Bioactivity Data
11.	ALA4806979	F	Antipsychotic activity in 129Sv/Ev mouse assessed as inhibition of MK801-induced disruption of prepulse inhibition at 10 mg/kg, po co-administered with haloperidol at 15 mins prior to MK801 challenge and measured after 15 mins	Mus musculus	1		organism-based format	Patent Bioactivity Data
12.	ALA4806981	A	Induction of catalepsy in Sprague-Dawley rat assessed as increase in latency to move both forepaws at 5 to 100 mg/kg, po measured after 45 mins	Rattus norvegicus	1		organism-based format	Patent Bioactivity Data
13.	ALA4806983	A	Induction of hyperprolactinemia in Sprague-Dawley rat assessed as increase in prolactin release in plasma at 1 to 100 mg/kg, po measured after 60 mins by ELISA	Rattus norvegicus	1		organism-based format	Patent Bioactivity Data
14.	ALA4806984	F	Inhibition of haloperidol-induced hyperprolactinemia in Sprague-Dawley rat assessed as reduction in prolactin release in plasma at 10 mg/kg, po administered 30 mins prior to 0.3 mg/kg haloperidol challenge and measured after 60 mins by ELISA	Rattus norvegicus	1		organism-based format	Patent Bioactivity Data
15.	ALA4806985	A	Ratio of drug level in brain to plasma in C57BL/6 mouse at 3 mg/kg, po measured after 60 mins by LC/MS/MS analysis	Mus musculus	2		organism-based format	Patent Bioactivity Data